Benefits
Antioxidant Defense
This is the one benefit measured directly in people's blood. In 50 adults with fatty liver, 2 months of grape seed extract raised total antioxidant capacity, superoxide dismutase and glutathione peroxidase more than placebo did, and the paper also reports larger falls in malondialdehyde and interleukin-6. The placebo group moved in the same direction on several of these markers, so the gaps are narrow. That is a single 50-person study at one clinic, using a generic extract rather than BeGrape, and it measured blood chemistry rather than how anyone felt.
Healthy Blood Pressure
The effect is real but small, and it is not consistent. Pooling 19 controlled trials, grape seed extract lowered diastolic pressure by 2.20 mmHg and heart rate by 1.25 bpm, but the 3.55 mmHg change in systolic pressure was not statistically significant and the trials disagreed sharply with each other. In the single trial most often quoted for this benefit, 300 mg/day for 16 weeks missed its own primary endpoint: systolic pressure fell 3.90 mmHg on the extract and 3.21 mmHg on placebo, p = 0.72 between groups. A separate trial gave 70 adults with pre- and stage I hypertension the same 300 mg/day for 8 weeks and found no significant change in 24-hour blood pressure either.
Circulation and Leg Vein Comfort
Two randomized trials have tested oral grape seed extract at 300 mg/day in people with vein problems in the legs. In 176 patients with varicose veins, 12 weeks shortened venous reflux time and improved symptom and quality-of-life scores compared with lifestyle changes alone, but that trial was open-label with no dummy capsule. In 303 patients with chronic venous disease, 8 weeks worked about as well as micronized purified flavonoid fraction, a standard vein drug, though again there was no placebo group and both groups improved. Cochrane's 2020 review of oral vein agents found only one of its 56 analysable trials had used grape seed extract. Blood vessel dilation itself, measured as flow-mediated dilation, did not change in pooled data from 19 trials.
Metabolic and Liver Support
One randomized trial gave 520 mg/day for 2 months to 50 adults with non-alcoholic fatty liver disease. Against placebo, the extract group had larger falls in insulin, HOMA-IR, total cholesterol, triglycerides and LDL, a larger rise in HDL, and less severe fatty change on imaging (p = 0.002). This is one small trial at one clinic in Iran and it has not been repeated elsewhere.
Stress Resilience
In a 16-week trial of 80 adults with mildly raised blood pressure, the worries subscale of the Perceived Stress Questionnaire fell from 16.5 to 13.7 on 300 mg/day of extract while edging up on placebo, a between-group difference of p = 0.025. This was a secondary outcome in a trial whose main blood-pressure endpoint was null, and it was designed and written by employees of the company that makes that particular extract, so it needs independent confirmation.
Mechanism of action
Endothelial Nitric Oxide Support
Grape seed proanthocyanidins increase endothelial nitric oxide synthase (eNOS) activity in laboratory models, which is the proposed explanation for the small blood-pressure effect. The middle step has not been demonstrated in people: pooled trial data show no significant change in flow-mediated dilation.
Free-Radical Scavenging
The oligomeric structure of grape seed procyanidins makes them efficient electron donors that quench reactive oxygen species and spare endogenous antioxidants.
Anti-Inflammatory Signaling
In cell and animal work, OPCs down-regulate pro-inflammatory mediators. In people, the one inflammatory marker measured in the fatty liver trial, interleukin-6, fell further on the extract than on placebo, but the placebo group's fall was almost as large.
Capillary and Collagen Protection
Proanthocyanidins bind collagen and elastin in the laboratory and reduce capillary fragility in animal models. This is the traditional rationale for the circulatory uses. Trials in people have measured leg vein symptoms rather than capillary fragility itself, so the mechanism is inferred rather than demonstrated.
Clinical trials
Randomized, double-blind, placebo-controlled trial of Enovita, a standardized grape seed extract made by Indena SpA, in 80 adults: 300 mg/day in two 150 mg tablets, or placebo, for 16 weeks. Three of the five authors are Indena employees and the other two work for the contract research organization that ran the study.
80 adults aged 40 to 70, 45 men and 35 women, with mildly raised systolic pressure of 125 to 140 mmHg and not on blood-pressure medication. The women were postmenopausal.
The primary endpoint was not met. Systolic pressure fell 3.90 mmHg on the extract and 3.21 mmHg on placebo, p = 0.72 between groups. Split by sex, men on the extract were 4.6 mmHg lower than placebo at 16 weeks, though the overall product effect in men was only a trend (p = 0.07), and in women placebo did as well as the extract. Perceived stress on the questionnaire's worries subscale did improve more than placebo, p = 0.025. The extract was well tolerated.
Randomized, double-blind, placebo-controlled trial in Ahvaz, Iran: 50 adults, 25 per group, 520 mg/day of grape seed extract or placebo for 2 months. This paper reports the oxidative-stress and quality-of-life results. The same 50 patients were reported separately for the metabolic, liver-enzyme and blood-pressure results, so the two papers describe one trial.
50 Iranian adults with non-alcoholic fatty liver disease, average age about 44 years.
Total antioxidant capacity, superoxide dismutase and glutathione peroxidase rose more, and malondialdehyde and interleukin-6 fell more, than on placebo. The placebo group moved in the same direction on several of these markers, so the gaps are small. Scores for physical limitations, general health and total physical health on the SF-36 questionnaire also improved more than placebo. Liver enzymes and fatty change were measured in the companion paper on the same 50 patients, not in this one.
Randomized trial in 72 patients in Bhubaneswar, India, of whom 64 finished. The extract was applied into the gum pocket during a dental cleaning, not taken by mouth, so it says nothing about what a swallowed supplement does. It appeared in a guest supplement issue of the Journal of Biological Regulators and Homeostatic Agents, the journal that in 2020 published and then retracted a paper claiming 5G technology induces coronavirus in skin cells, so it should not be weighted alongside the other two studies.
72 adults with periodontal pockets, average age 39.2 years, treated in a dental clinic.
At 3 months, pocket depth (p = 0.002) and relative attachment level (p = 0.01) improved more than cleaning alone. Plaque index and gingival index, the measure of gum inflammation, showed no significant difference. No antioxidant or inflammatory marker was measured in this study.